MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01DAB1FB.AD3D14E0"

Данный документ является веб-страницей в одном файле, также называемой файлом веб-архива. Если вы видите это сообщение, значит, данный браузер или редактор не поддерживает файлы веб-архива. Загрузите браузер, поддерживающий веб-архивы, например Windows® Internet Explorer®.

------=_NextPart_01DAB1FB.AD3D14E0
Content-Location: file:///C:/680CD8A5/UA41170201_84CE.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link rel=3DFile-List href=3D"UA41170201_84CE.files/filelist.xml">
<link rel=3DPreview href=3D"UA41170201_84CE.files/preview.wmf">
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>User</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Bravada</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>5</o:TotalTime>
  <o:LastPrinted>2022-09-06T09:58:00Z</o:LastPrinted>
  <o:Created>2024-05-29T16:09:00Z</o:Created>
  <o:LastSaved>2024-05-29T16:09:00Z</o:LastSaved>
  <o:Pages>4</o:Pages>
  <o:Words>1640</o:Words>
  <o:Characters>9353</o:Characters>
  <o:Company>CtrlSoft</o:Company>
  <o:Lines>77</o:Lines>
  <o:Paragraphs>21</o:Paragraphs>
  <o:CharactersWithSpaces>10972</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=3DdataStoreItem href=3D"UA41170201_84CE.files/item0001.xml"
target=3D"UA41170201_84CE.files/props002.xml">
<link rel=3DthemeData href=3D"UA41170201_84CE.files/themedata.thmx">
<link rel=3DcolorSchemeMapping href=3D"UA41170201_84CE.files/colorschememap=
ping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>RU</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:DontUseIndentAsNumberingTabStop/>
   <w:FELineBreak11/>
   <w:WW11IndentRules/>
   <w:DontAutofitConstrainedTables/>
   <w:AutofitLikeWW11/>
   <w:HangulWidthLikeWW11/>
   <w:UseNormalStyleForList/>
   <w:DontVertAlignCellWithSp/>
   <w:DontBreakConstrainedForcedTables/>
   <w:DontVertAlignInTxbx/>
   <w:Word11KerningPairs/>
   <w:CachedColBalance/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val=3D"Cambria Math"/>
   <m:brkBin m:val=3D"before"/>
   <m:brkBinSub m:val=3D"&#45;-"/>
   <m:smallFrac m:val=3D"off"/>
   <m:dispDef/>
   <m:lMargin m:val=3D"0"/>
   <m:rMargin m:val=3D"0"/>
   <m:defJc m:val=3D"centerGroup"/>
   <m:wrapIndent m:val=3D"1440"/>
   <m:intLim m:val=3D"subSup"/>
   <m:naryLim m:val=3D"undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" DefUnhideWhenUsed=3D"true"
  DefSemiHidden=3D"true" DefQFormat=3D"false" DefPriority=3D"99"
  LatentStyleCount=3D"267">
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Normal"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"heading 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" QFormat=3D"true" Name=3D"=
heading 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"35" QFormat=3D"true" Name=3D=
"caption"/>
  <w:LsdException Locked=3D"false" Priority=3D"10" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" Name=3D"Default Paragraph=
 Font"/>
  <w:LsdException Locked=3D"false" Priority=3D"11" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtitle"/>
  <w:LsdException Locked=3D"false" Priority=3D"22" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Strong"/>
  <w:LsdException Locked=3D"false" Priority=3D"20" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Table Grid"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Placeho=
lder Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"No Spacing"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Revisio=
n"/>
  <w:LsdException Locked=3D"false" Priority=3D"34" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"List Paragraph"/>
  <w:LsdException Locked=3D"false" Priority=3D"29" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"30" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"19" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"21" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"31" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"32" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"33" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Book Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"37" Name=3D"Bibliography"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" QFormat=3D"true" Name=3D=
"TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-134238209 -371195905 63 0 4129279 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520092929 1073786111 9 0 415 0;}
@font-face
	{font-family:"DejaVu Sans";
	mso-font-alt:"Times New Roman";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520084737 -1073683329 41 0 479 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-134238209 -371195905 63 0 4129279 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
h3
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Заголовок 3 Знак";
	mso-style-next:Обычный;
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:none;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:RU;
	mso-fareast-language:RU;
	font-weight:normal;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-priority:99;
	mso-style-link:"Верхний колонтитул Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 240.95pt right 17.0cm;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-priority:99;
	mso-style-link:"Нижний колонтитул Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 240.95pt right 17.0cm;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Arial Unicode MS";
	mso-ansi-language:UK;
	mso-fareast-language:UK;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Текст выноски Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Segoe UI","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	mso-add-space:auto;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParag=
raphCxSpFirst
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListPar=
agraphCxSpMiddle
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagra=
phCxSpLast
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	mso-add-space:auto;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
span.a
	{mso-style-name:"Верхний колонтитул Знак";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Верхний колонтитул";}
span.a0
	{mso-style-name:"Нижний колонтитул Знак";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Нижний колонтитул";}
span.a1
	{mso-style-name:"Текст выноски Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Текст выноски";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Segoe UI","sans-serif";
	mso-ascii-font-family:"Segoe UI";
	mso-hansi-font-family:"Segoe UI";
	mso-bidi-font-family:"Segoe UI";}
span.3
	{mso-style-name:"Заголовок 3 Знак";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Заголовок 3";
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:RU;
	mso-fareast-language:RU;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	mso-ascii-font-family:Calibri;
	mso-fareast-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("UA41170201_84CE.files/header.htm") fs;
	mso-footnote-continuation-separator:url("UA41170201_84CE.files/header.htm"=
) fcs;
	mso-endnote-separator:url("UA41170201_84CE.files/header.htm") es;
	mso-endnote-continuation-separator:url("UA41170201_84CE.files/header.htm")=
 ecs;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:42.5pt 42.5pt 42.5pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-footer:url("UA41170201_84CE.files/header.htm") f1;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:88550773;
	mso-list-type:hybrid;
	mso-list-template-ids:-2097615316 -1 68747267 68747269 68747265 68747267 6=
8747269 68747265 68747267 68747269;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
@list l0:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1
	{mso-list-id:387538824;
	mso-list-type:hybrid;
	mso-list-template-ids:-1626686734 -31263442 69337091 69337093 69337089 693=
37091 69337093 69337089 69337091 69337093;}
@list l1:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
@list l1:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2
	{mso-list-id:436877467;
	mso-list-type:hybrid;
	mso-list-template-ids:1015049580 -1 68747267 68747269 68747265 68747267 68=
747269 68747265 68747267 68747269;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
@list l2:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3
	{mso-list-id:1361711032;
	mso-list-type:hybrid;
	mso-list-template-ids:-1594699484 -490317902 69337091 69337093 69337089 69=
337091 69337093 69337089 69337091 69337093;}
@list l3:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
@list l3:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l3:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l3:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l4
	{mso-list-id:2123265189;
	mso-list-type:hybrid;
	mso-list-template-ids:-1336359794 68747265 68747267 68747269 68747265 6874=
7267 68747269 68747265 68747267 68747269;}
@list l4:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
@list l4:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Обычная таблица";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DRU style=3D'tab-interval:35.4pt'>

<div class=3DWordSection1>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-outline-level:1'><b><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";text-transf=
orm:
uppercase;mso-fareast-language:UK'>ІНСТРУКЦІЯ<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:6.0pt;text-align=
:center;
line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-language:
UK'>для медичного застосування лікарського засобу<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><b style=3D'mso-bidi-font-weight:norm=
al'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>ДОЛГІТ<sup>®</sup> ГЕЛЬ <o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><b style=3D'mso-bidi-font-weight:norm=
al'><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-fareast-langua=
ge:UK'>(DOLGIT<sup>®</sup>
GEL)<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-fareast-langua=
ge:UK'>&nbsp;<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-fareast-langua=
ge:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-family:"Times New Roman","serif";mso-fareast-langua=
ge:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:11.=
5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK'>Склад: <o:p>=
</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>діюча речовина:</span></i><span lang=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";mso-fareast=
-language:
UK'> ібупрофен; <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>1 г гелю містить ібупроф=
ену
50 мг; <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>допоміжні речовини: </span></i><span lang=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"DejaVu Sans";mso-font-kerning:1.0pt;mso-fareast-language:AR-SA'>2-пропанол=
, солкетал,
полоксамер, тригліцериди середнього ланцюга</span><span lang=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";mso-fareast=
-language:
UK'>, </span><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Times N=
ew Roman","serif";
mso-fareast-font-family:"DejaVu Sans";mso-font-kerning:1.0pt;mso-fareast-la=
nguage:
AR-SA'>олія лавандова, олія неролова, </span><span lang=3DUK style=3D'font-=
size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-language:UK'>вода
очищена. </span><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Time=
s New Roman","serif";
mso-fareast-font-family:"DejaVu Sans";mso-font-kerning:1.0pt;mso-fareast-la=
nguage:
AR-SA'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>&nbsp;<o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><b style=3D'mso-bidi-font-w=
eight:
normal'><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Ro=
man","serif";
mso-fareast-language:UK'>Лікарська форма.</span></b><span lang=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";mso-fareast=
-language:
UK'> Гель.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Основні фізико-хімічні властивості:</span></i><span
lang=3DUK style=3D'font-size:11.5pt'> </span><span lang=3DUK style=3D'font-=
size:11.5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK'>прозорий,
безбарвний або злегка каламутний, з характерним запахом гелю.<o:p></o:p></s=
pan></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'><o:p>&nbsp;</o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><span lang=3DUK style=3D'font-size:11.5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK'>Фармакотерап=
евтична
група. </span></b><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Ti=
mes New Roman","serif";
mso-fareast-language:UK'>Засоби для місцевого застосування при суглобовому =
та м’язовому
болю. Код АТХ M02A A13.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:11.=
5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK'>Фармакологіч=
ні
властивості.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Фармакодинаміка.<span
style=3D'mso-spacerun:yes'>                                   </span><o:p><=
/o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>«Долгіт<b style=3D'mso-b=
idi-font-weight:
normal'><sup>®</sup></b> гель» – лікарський засіб для місцевого застосування
при суглобовому та м’язовому болю ревматичного та неревматичного походження.
Чинить виражену протизапальну, анальгетичну та помірну жарознижувальну дію,
зменшує набряк, який виникає при запаленні, спричиненому травмами чи
ревматичними захворюваннями, покращує рухливість суглобів. Фармакологічна
активність препарату зумовлена його здатністю пригнічувати синтез
простагландинів. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>При зовнішньому застосув=
анні
ібупрофен швидко всмоктується через шкіру і проникає у вогнище запалення. П=
роникнення
до місця дії може варіюватися залежно від ступеня та виду ураження, а
також<span style=3D'mso-spacerun:yes'>  </span>від ділянки застосування та =
місця
дії.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>У суглобових тканинах
терапевтичні концентрації тримаються протягом кількох годин, у той час як у
сироватці крові діюча речовина становить лише незначну кількість, тому сист=
емна
дія практично відсутня.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Фармакокінетика.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Біологічна трансформація
ібупрофену відбувається у печінці. Фармакологічно неактивні метаболіти
видаляються нирками (90 %), а також з жовчю. <span
style=3D'mso-spacerun:yes'> </span>Ібупрофен зв’язується на 99 % з білками =
плазми
крові. Період напіввиведення становить 1,8–3,5 години. <o:p></o:p></span></=
p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Клінічні характеристики.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Показання.</span></i></b><b><span lang=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";mso-fareast=
-language:
UK'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK;mso-bidi-font-weight:bold=
'>Для
місцевого лікування при</span><span lang=3DUK style=3D'font-size:11.5pt;fon=
t-family:
"Times New Roman","serif";mso-fareast-language:UK'> спортивних та інших
травмах, таких як перенапруження м’язів, <span
style=3D'mso-spacerun:yes'> </span>розтягнення зв’язок, с</span><span lang=
=3DUK
style=3D'font-family:"Times New Roman","serif";mso-fareast-font-family:"Tim=
es New Roman";
mso-fareast-language:UK'>ухожилля</span><span lang=3DUK style=3D'font-size:=
11.5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK'> або забій, =
при дегенеративних
захворюваннях суглобів з больовим синдромом (артрози),<span style=3D'mso-bi=
di-font-weight:
bold'> </span>запальних ревматичних захворюваннях суглобів і хребта, набряку
або запаленні м’яких тканин біля суглобів (наприклад, при бурситі, тендиніт=
і,
тендовагініті, ураженні зв’язок і суглобової капсули), скутості рухів у діл=
янці
плеча, болю у попереку, люмбаго, міалгії. <span style=3D'mso-bidi-font-weig=
ht:
bold'><o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Протипоказання. <o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
RU;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>«Долгіт<sup>®</sup>
гель» протипоказаний:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
UK'>– при підвищеній індивідуальній чутливості до активної речовини ібупроф=
ену,
до будь-якої з допоміжних речовин лікарського засобу або до інших анальгети=
ків
та протиревматичних засобів (нестероїдні протизапальні лікарські засоби);<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
UK'>–<span style=3D'mso-spacerun:yes'>  </span>для застосування на відкриті=
 рани,
при запальних<span style=3D'mso-spacerun:yes'>  </span>та інфекційних
захворюваннях<span style=3D'mso-spacerun:yes'>  </span>шкіри, таких як екзе=
ма, а
також для застосування на слизові оболонки;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
UK'>– <span style=3D'mso-spacerun:yes'> </span>для застосування під оклюзій=
ну
пов’язку;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
UK'>– <span style=3D'mso-spacerun:yes'> </span>у третьому триместрі вагітно=
сті.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:11.=
5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK'>Взаємодія з
іншими лікарськими засобами та інші види взаємодій.<o:p></o:p></span></i></=
b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>При зовнішньому застосуванні препарату згідно з
рекомендаціями взаємодії з іншими лікарськими засобами не спостерігалося.<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>Необхідно повідомити лікаря про одночасне лікування
іншими лікарськими засобами, якщо таке відбувається, або про нещодавно
проведену терапію.<o:p></o:p></span></p>

<p style=3D'margin:0cm;margin-bottom:.0001pt;text-align:justify'><b><i><span
lang=3DUK style=3D'font-size:11.5pt'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:11.=
5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK'>Особливості
застосування.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>У пацієнтів з <span
style=3D'mso-spacerun:yes'> </span>астмою, сінною гарячкою, набряком слизов=
ої
оболонки носа (так звані ринополіпи), <span
style=3D'mso-spacerun:yes'> </span>хронічними обструктивними захворюваннями
дихальних шляхів або хронічними інфекціями дихальних шляхів </span><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>(особлив=
о з
симптомами, які нагадують сінну гарячку)</span><span lang=3DUK style=3D'fon=
t-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-language:UK'> та у
пацієнтів з гіперчутливістю до анальгетиків і протиревматичних препаратів р=
ізного
типу більший ризик розвитку астматичних нападів (так звані непереносимість
анальгетиків/ анальгетична астма), місцевих набряків шкіри та слизових обол=
онок
(набряк Квінке) або кропив’янки. Застосування препарату таким пацієнтам
необхідно проводити під контролем лікаря. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Слід з обережністю
застосовувати препарат пацієнтам з гіперчутливістю (алергією) на інші речов=
ини,
що спричиняють подразнення шкіри, свербіж, кропив’янку.</span><span lang=3D=
UK> </span><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>У разі появи<span style=3D'mso-spacerun:yes'> 
</span>висипу на шкірі слід негайно припинити застосування гелю.<span
style=3D'mso-spacerun:yes'>  </span><span style=3D'mso-spacerun:yes'>  </sp=
an><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK;mso-bidi-font-weight:bold=
'>При&nbsp;
застосуванні ібупрофену</span><span lang=3DUK style=3D'font-size:11.5pt;fon=
t-family:
"Times New Roman","serif";mso-fareast-language:UK'> <span style=3D'mso-bidi=
-font-weight:
bold'>були зареєстровані</span> тяжкі шкірні побічні реакції,</span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Segoe UI","sans-serif";mso=
-fareast-font-family:
"Times New Roman";letter-spacing:.25pt'> </span><span lang=3DUK style=3D'fo=
nt-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-language:UK'>зокре=
ма
ексфоліативний дерматит, мультиформна еритема, синдром Стівенса — Джонсона,
токсичний епідермальний некроліз,&nbsp;&nbsp;медикаментозна реакція з
еозинофілією і системними симптомами (DRESS-синдром)&nbsp;<span
style=3D'mso-bidi-font-weight:bold'>та</span>&nbsp;гострий генералізований
екзантематозний пустульоз,&nbsp;<span style=3D'mso-bidi-font-weight:bold'>я=
кі
можуть становити загрозу для життя або призвести до летального наслідку</sp=
an> (див.
розділ «Побічні реакції»).&nbsp; <span style=3D'mso-bidi-font-weight:bold'>=
Більшість
таких реакцій виникали</span>&nbsp;<span style=3D'mso-bidi-font-weight:bold=
'>впродовж&nbsp;</span>
першого місяця.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK;mso-bidi-font-weight:bold=
'>У
разі появи ознак та симптомів, що вказують на ці реакції</span><span lang=
=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";mso-fareast=
-language:
UK'>, застосування ібупрофену слід негайно припинити&nbsp;<span
style=3D'mso-bidi-font-weight:bold'>і</span>&nbsp;<span style=3D'mso-bidi-f=
ont-weight:
bold'>розглянути можливість альтернативного лікування (якщо потрібно).</spa=
n>&nbsp;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Не допускати потрапляння
препарату в очі. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK;mso-bidi-font-weight:bold=
'>Необхідно
звернути увагу на те, щоб діти не торкалися<span style=3D'mso-spacerun:yes'=
> 
</span>ділянок шкіри, на які було нанесено препарат. </span><s><span lang=
=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif"'><o:p></o:p=
></span></s></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif"'>Якщо дискомфорт при лікуванні триває довше 3 дні=
в,
слід проконсультуватися з лікарем.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif"'>Через можливе виникнення надмірної світлочутливо=
сті
пацієнтам слід уникати інтенсивного впливу сонячного світла / УФ-променів п=
ри
застосуванні препарату.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:6.0pt;text-align:justify;line-h=
eight:
normal'><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Ro=
man","serif"'>Цей
лікарський засіб містить ароматизатори (</span><span lang=3DUK style=3D'fon=
t-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-font-family:"DejaV=
u Sans";
mso-font-kerning:1.0pt;mso-fareast-language:AR-SA'>олія лавандова та<span
style=3D'mso-spacerun:yes'>  </span>олія неролова)</span><span lang=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif"'> з бензило=
вим
спиртом, бензилбензоатом, цитралем, цитронелолом, кумарином, евгенолом,
фарнезолом, гераніолом, лимоненом/d-лимоненом, ліналоолом, які можуть викли=
кати
алергічні реакції. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Застосування у період вагітності або годування гру=
ддю.</span></i><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'> <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><u><span lang=3DUK style=3D'font-size:11.5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK'>Вагітність <=
span
style=3D'mso-spacerun:yes'> </span><span style=3D'mso-spacerun:yes'> </span=
><o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Клінічних даних щодо міс=
цевого
застосування лікарського засобу «Долгіт<sup>®</sup> гель» під час вагітност=
і немає.
Навіть якщо системна експозиція є нижчою порівняно з пероральним застосуван=
ням,
невідомо, чи може системна експозиція лікарського засобу «Долгіт<sup>®</sup>
гель», досягнута після місцевого застосування, бути шкідливою для
ембріона/плода. Під час першого та другого триместру вагітності «Долгіт<sup=
>®</sup>
гель» не слід застосовувати без нагальної потреби. У разі застосування доза
повинна бути якомога нижчою, а тривалість лікування — якомога коротшою.<o:p=
></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Системне застосування
інгібіторів простагландинсинтетази, зокрема лікарського засобу «Долгіт<sup>=
®</sup>
гель», під час третього триместру вагітності може спричинити серцево-легене=
ву
та ниркову токсичність у плода. Наприкінці вагітності може виникнути тривала
кровотеча як у матері, так і у дитини, а також затримка пологів. Тому «Долг=
іт<sup>®</sup>
гель» протипоказаний під час останнього триместру вагітності (див. розділ
«Протипоказання»).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><u><span lang=3DUK style=3D'font-size:11.5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK'>Грудне годув=
ання
<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Тільки незначна кількість
активних похідних ібупрофену і продуктів його розпаду проникає у грудне мол=
око.
На даний момент даних про негативний вплив на новонародженого немає, тому у
разі короткочасного лікування немає необхідності переривати годування грудд=
ю.
Проте добову дозу при триразовому застосуванні смужки гелю довжиною 4–10 см=
 не
можна перевищувати, а у разі тривалого лікування необхідно перервати годува=
ння
груддю. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:6.0pt;text-align:justify;line-h=
eight:
normal'><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Ro=
man","serif";
mso-fareast-language:UK'>Жінки, що годують груддю, не повинні застосовувати=
 цей
лікарський засіб у ділянці<span style=3D'mso-spacerun:yes'>  </span>грудей,=
 щоб
уникнути потрапляння цього препарату в організм немовляти.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Здатність впливати на швидкість реакції при керува=
нні
автотранспортом або іншими механізмами. <o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Лікарський засіб не впли=
ває<i
style=3D'mso-bidi-font-style:normal'> </i>на здатність керувати автотранспо=
ртом
та працювати з потенційно небезпечними механізмами.<i style=3D'mso-bidi-fon=
t-style:
normal'><o:p></o:p></i></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>&nbsp;<o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Спосіб застосування та дози.<o:p></o:p></span></i>=
</b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Arial Unicode MS";
mso-fareast-language:UK'>Тільки для зовнішнього застосування. </span><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Лікарський засіб застосовувати 3–4 рази на добу.</=
span><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Arial Unicode MS";mso-fareast-language:UK'><o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:99.25pt'><span lang=3DUK style=3D'font=
-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-language:UK'>Залеж=
но
від величини ураженої ділянки гель наносити тонким шаром на шкіру у ділянці
запалення/болю смужками довжиною 4–10 см (що відповідає 2–5 г гелю, або 100=
–250
мг ібупрофену) </span><span lang=3DUK style=3D'font-size:11.5pt;font-family=
:"Times New Roman","serif"'>з
подальшим легким втиранням до повного всмоктування</span><span lang=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";mso-fareast=
-language:
UK'>. Максимальна добова доза становить 20 г гелю (що відповідає 1 000 мг і=
бупрофену).
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:99.25pt'><span lang=3DUK style=3D'font=
-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-language:UK'>Трива=
лість
лікування визначає лікар. У більшості випадків термін лікування становить 1=
–2
тижні. </span><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Times =
New Roman","serif"'>Даних
про терапевтичну користь від застосування лікарського засобу протягом більш
тривалого часу немає. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:99.25pt'><span lang=3DUK style=3D'font=
-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-language:UK'>Не за=
стосовувати
під оклюзійну пов’язку.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Проникнення активного
компонента може бути підсилено за допомогою іонофорезу (спеціальна форма
електротерапії). У такому випадку препарат наносити під катод (негативний е=
лектрод),
інтенсивність струму <span style=3D'mso-spacerun:yes'> </span>0,1–0,5 mА на=
 5 см<sup>2
</sup>поверхні електрода, тривалість процедури – до 10 хвилин.<o:p></o:p></=
span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Після нанесення гелю на
шкіру потрібно витерти руки паперовим рушником, а потім вимити, якщо вони н=
е є
об’єктом лікування. Паперовий рушник слід утилізувати разом із відходами.<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Перш ніж приймати душ або
ванну, пацієнт повинен почекати, поки активна речовина вбереться.<o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Діти.</span></i><span lang=3DUK style=3D'font-size=
:11.5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK'> <o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Не застосовувати дітям в=
іком
до 14 років.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:11.=
5pt;
font-family:"Times New Roman","serif";mso-fareast-language:UK;mso-no-proof:
yes'>Передозування.</span></i></b><i style=3D'mso-bidi-font-style:normal'><=
span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'> <o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>У разі нанесення більшої
кількості гелю, ніж рекомендовано, необхідно видалити залишки гелю<span
style=3D'mso-spacerun:yes'>  </span>та промити шкіру<span
style=3D'mso-spacerun:yes'>  </span>водою. При застосуванні дуже великої
кількості або при випадковому внутрішньому прийомі гелю необхідно повідомити
про це лікаря. Специфічний антидот невідомий.<b style=3D'mso-bidi-font-weig=
ht:
normal'><o:p></o:p></b></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Побічні реакції.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Класифікація побічних ре=
акцій
за частотою виникнення: дуже часті (&#8805; 1/10), часті (&#8805; 1/100, &l=
t;
1/10), нечасті (&#8805; 1/1 000, &lt; 1/100), поодинокі (&#8805; 1/10 000, =
&lt;
1/1 000), рідкісні (&lt; 1/10 000), частота невідома.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Розлади з боку імунної системи<o:p></o:p></span></=
i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Нечасті: такі реакції
гіперчутливості, як місцеві алергічні реакції (контактні дерматити).<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Розлади з боку органів дихання, грудної клітки та
середостіння<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Рідкісні: бронхоспастичні
реакції.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Розлади з боку шкіри та підшкірної клітковини<o:p>=
</o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Часті: такі місцеві
реакції,<span style=3D'mso-spacerun:yes'>  </span>як почервоніння шкіри, св=
ербіж,
відчуття печіння, екзантема, у т. ч. з утворенням пустул та пухирців. <o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Рідкісні:</span><span
lang=3DUK> </span><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Ti=
mes New Roman","serif";
mso-fareast-language:UK'>тяжкі шкірні побічні реакції (зокрема мультиформна
еритема, ексфоліативний дерматит, синдром Стівенса — Джонсона та токсичний
епідермальний некроліз).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Частота невідома: реакції
світлочутливості; медикаментозна реакція з еозинофілією і системними симпто=
мами
(DRESS-синдром); гострий генералізований екзантематозний пустульоз.<o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>При застосуванні препара=
ту «Долгіт<sup>®</sup>
гель» на великі ділянки шкіри та протягом тривалого часу не можуть бути
виключені побічні реакції, які впливають на певні органи або організм у ціл=
ому
та <span style=3D'mso-spacerun:yes'> </span>можливі при системному застосув=
анні
лікарських засобів, що містять ібупрофен.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><i style=3D'mso-bidi-font-s=
tyle:
normal'><u><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New=
 Roman","serif";
mso-fareast-language:UK'>Повідомлення про підозрювані побічні реакції<o:p><=
/o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-language:UK'>Повід=
омлення
про побічні реакції після реєстрації лікарського засобу має велике значення=
. Це
дає змогу проводити моніторинг співвідношення користь/ризик при застосуванні
цього лікарського засобу. Медичним та фармацевтичним працівникам, а також
пацієнтам або їхнім законним представникам слід повідомляти про усі випадки
підозрюваних побічних реакцій та відсутності ефективності лікарського засобу
через Автоматизовану інформаційну систему з фармаконагляду за посиланням:
https://aisf.dec.gov.ua.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><b style=3D'mso-bidi-font-w=
eight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-language:UK'><o:p>=
&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><b style=3D'mso-bidi-font-w=
eight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-language:UK'>Термін
придатності.</span></i></b><i style=3D'mso-bidi-font-style:normal'><span la=
ng=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";mso-fareast=
-language:
UK'> </span></i><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Time=
s New Roman","serif";
mso-fareast-language:UK'>30 місяців.<b style=3D'mso-bidi-font-weight:normal=
'><o:p></o:p></b></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Умови зберігання. </span></b><span lang=3DUK
style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";mso-fareast=
-language:
UK'>Зберігати <span style=3D'mso-spacerun:yes'> </span>в оригінальній упако=
вці
при температурі не вище 25 °С.<b style=3D'mso-bidi-font-weight:normal'><o:p=
></o:p></b></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK;mso-bidi-font-weight:bold=
'>Зберігати
у недоступному для дітей місці.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK;mso-bidi-font-weight:bold=
'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Упаковка. </span></b><span lang=3DUK style=3D'font=
-size:
11.5pt;font-family:"Times New Roman","serif";mso-fareast-language:UK'>По 20=
 г
або 50 г, або 100 г, або 150 г у тубі; по 1 тубі в картонній коробці.<b
style=3D'mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Категорія відпуску.</span></b><span lang=3DUK
style=3D'font-size:11.5pt'> </span><span lang=3DUK style=3D'font-size:11.5p=
t;
font-family:"Times New Roman","serif";mso-fareast-language:UK'>Без рецепта.=
<b
style=3D'mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Виробник. <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Долоргіт ГмбХ і Ко. КГ/ =
Dolorgiet
GmbH &amp; Co. KG.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'><o:p>&nbsp;</o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Roman","serif";
mso-fareast-language:UK'>Місцезнаходження виробника та адреса місця провадж=
ення
його діяльності.</span></b><span lang=3DUK style=3D'font-size:11.5pt;font-f=
amily:
"Times New Roman","serif";mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:11.5pt;font-=
family:
"Times New Roman","serif";mso-fareast-language:UK'>Отто фон Геріке штр. 1,
53757 Санкт Аугустін, Німеччина/<u><o:p></o:p></u></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK style=3D'font-size:11.5pt;font-family:"Times New Ro=
man","serif";
mso-fareast-language:UK'>Otto-von-Gueriсke-Str. 1, 53757 Sankt Augustin, Ge=
rmany.
<o:p></o:p></span></p>

</div>

</body>

</html>

------=_NextPart_01DAB1FB.AD3D14E0
Content-Location: file:///C:/680CD8A5/UA41170201_84CE.files/preview.wmf
Content-Transfer-Encoding: base64
Content-Type: image/x-wmf
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------=_NextPart_01DAB1FB.AD3D14E0
Content-Location: file:///C:/680CD8A5/UA41170201_84CE.files/item0001.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<b:Sources SelectedStyle=3D"\APA.XSL" StyleName=3D"APA" xmlns:b=3D"http://s=
chemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns=3D"http:/=
/schemas.openxmlformats.org/officeDocument/2006/bibliography"></b:Sources>

------=_NextPart_01DAB1FB.AD3D14E0
Content-Location: file:///C:/680CD8A5/UA41170201_84CE.files/props002.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{D79342DD-B726-4F5B-9307-4B564E4A3767}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.openxmlformats.org/offi=
ceDocument/2006/bibliography"/></ds:schemaRefs></ds:datastoreItem>
------=_NextPart_01DAB1FB.AD3D14E0
Content-Location: file:///C:/680CD8A5/UA41170201_84CE.files/themedata.thmx
Content-Transfer-Encoding: base64
Content-Type: application/vnd.ms-officetheme
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------=_NextPart_01DAB1FB.AD3D14E0
Content-Location: file:///C:/680CD8A5/UA41170201_84CE.files/colorschememapping.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"yes"?>
<a:clrMap xmlns:a=3D"http://schemas.openxmlformats.org/drawingml/2006/main"=
 bg1=3D"lt1" tx1=3D"dk1" bg2=3D"lt2" tx2=3D"dk2" accent1=3D"accent1" accent=
2=3D"accent2" accent3=3D"accent3" accent4=3D"accent4" accent5=3D"accent5" a=
ccent6=3D"accent6" hlink=3D"hlink" folHlink=3D"folHlink"/>
------=_NextPart_01DAB1FB.AD3D14E0
Content-Location: file:///C:/680CD8A5/UA41170201_84CE.files/header.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link id=3DMain-File rel=3DMain-File href=3D"../UA41170201_84CE.htm">
<![if IE]>
<base href=3D"file:///C:\680CD8A5\UA41170201_84CE.files\header.htm"
id=3D"webarch_temp_base_tag">
<![endif]>
</head>

<body lang=3DRU>

<div style=3D'mso-element:footnote-separator' id=3Dfs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK><span style=3D'mso-special-character:footnote-separ=
ator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:footnote-continuation-separator' id=3Dfcs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK><span style=3D'mso-special-character:footnote-conti=
nuation-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:endnote-separator' id=3Des>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK><span style=3D'mso-special-character:footnote-separ=
ator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:endnote-continuation-separator' id=3Decs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK><span style=3D'mso-special-character:footnote-conti=
nuation-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:footer' id=3Df1>

<p class=3DMsoFooter align=3Dcenter style=3D'text-align:center'><span lang=
=3DUK><span
style=3D'mso-tab-count:2'>                                                 =
                                                                           =
                                                                           =
             </span></span><!--[if supportFields]><span
lang=3DUK><span style=3D'mso-element:field-begin'></span>PAGE<span
style=3D'mso-spacerun:yes'>   </span>\* MERGEFORMAT<span style=3D'mso-eleme=
nt:field-separator'></span></span><![endif]--><span
style=3D'mso-ansi-language:RU;mso-no-proof:yes'>1</span><!--[if supportFiel=
ds]><span
lang=3DUK><span style=3D'mso-element:field-end'></span></span><![endif]--><=
/p>

<p class=3DMsoFooter><span lang=3DUK><o:p>&nbsp;</o:p></span></p>

</div>

</body>

</html>

------=_NextPart_01DAB1FB.AD3D14E0
Content-Location: file:///C:/680CD8A5/UA41170201_84CE.files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../UA41170201_84CE.htm"/>
 <o:File HRef=3D"preview.wmf"/>
 <o:File HRef=3D"item0001.xml"/>
 <o:File HRef=3D"props002.xml"/>
 <o:File HRef=3D"themedata.thmx"/>
 <o:File HRef=3D"colorschememapping.xml"/>
 <o:File HRef=3D"header.htm"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01DAB1FB.AD3D14E0--
